Na
Natl Cancer Ctr Singapore
NPSingapore SGFounded 20002,000 employees
Private CapacadPrivateOncology
Platform: Cancer Research
Market Cap
N/A
All Drugs
8
Clinical Trials
8
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (8 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| NAT-IIT-525 | NAT-IIT-525 | Phase 1/2 | 1 | TNFα | DLBCL | ||
| NAT-IIT-130 | NAT-IIT-130 | Phase 1/2 | 1 | EGFR | Fabry | ||
| NAT-IIT-296 | NAT-IIT-296 | Preclinical | 1 | GIP-R | NB | ||
| NAT-IIT-794 | NAT-IIT-794 | Approved | 1 | Cl18.2 | CML | ||
| NAT-IIT-452 | NAT-IIT-452 | Phase 3 | 1 | FXIa | GBM | ||
| NAT-IIT-330 | NAT-IIT-330 | Phase 2 | 1 | HER2 | GBM | ||
| NAT-IIT-130 | NAT-IIT-130 | Phase 1 | 1 | KIF18A | CTCL | ||
| NAT-IIT-714 | NAT-IIT-714 | Phase 3 | 1 | BET | Psoriasis |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)